An observational study in Brain Tumor, Vascular Lesion and Factor XIII Deficiency, sponsored by Ludwig-Maximilians - University of Munich. Status unknown at 1 site in Germany. Per ClinicalTrials.gov, last updated 2010-04-20.
Sponsored by Ludwig-Maximilians - University of Munich · Observational
Two studies (Gerlach et al. 2000; Gerlach et al. 2002) described the impact of factor XIII on the risk of prospective hemorrhage for patients undergoing craniotomy. Since then, factor XIII is measured and substituted in various centers. Few reports support the idea of factor XIII being involved in the formation of deep venous thrombosis and pulmonary embolism. In this prospective observational study, patients undergoing craniotomy for brain tumors or vascular lesions are investigated concerning the incidence of postoperative pulmonary embolism in respect of possible risk factors (factor XIII activity levels, standard coagulation parameters, tumor entity, blood loss).
1,993 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.
This study's planned enrollment of 130 is above the median of 100 across 389 observational studies indexed under Brain Neoplasms.
Browse Brain Neoplasms studies →Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Neurosurgical patients with a postoperative occurence of pulmonary embolism in with laboratory-confirmed preoperatively low levels of Factor XIII
Exclusion Criteria:
Postoperative occurence of pulmonary embolism in patients scheduled to undergo a neurosurgical procedure with laboratory-confirmed low levels of Factor XIII
Incidence of pulmonary embolisms following Factor XIII substitution
Time frame: 38 months
This study is status unknown, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ludwig-Maximilians - University of Munich →